A Study of NGM282 When Given to Subjects with Functional Constipation and to Healthy Individuals


About this study

The purpose of this study is to determine the effect of NGM282 on colonic transit, bile acid homeostasis, and fecal fat in subjects with functional constipation and in healthy individuals.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Functional constipation confirmed by modified Rome III criteria 
  • Healthy Volunteer

Exclusion Criteria

  • Structural or metabolic diseases/conditions that affect the GI system
  • Diagnosis of dyspepsia, IBS, or significant gastrointestinal symptoms

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Michael Camilleri, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer